This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossing, M. A. Articles by Weiss, N. S. Search for Related Content PubMed PubMed Citation Articles by Rossing, M. A. Articles by Weiss, N. S. Related Collections Commentary

Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer

¹ Program in Epidemiology, Fred Hutchinson Cancer Research Center; and ² Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington

Requests for reprints: Mary Anne Rossing, Program in Epidemiology, Fred Hutchinson Cancer Research Center, P.O. Box 19024, Seattle, WA 98108-1024. Phone: 206-667-5041; Fax: 206-667-5948. E-mail: mrossing{at}fhcrc.org

Substantial increase in the use of menopausal hormone therapy (HT) throughout the 1990s, followed by widespread discontinuation after the 2002 publication of the Women's Health Initiative findings, has resulted in large numbers of former HT users among U.S. women. However, few studies have examined whether ovarian cancer risk varies according to recency and duration of specific HT regimens. We assessed risk of epithelial ovarian cancer among users of unopposed estrogen (ET) and combined estrogen/progestogen (EPT). In a population-based study in Washington state, 812 women with ovarian cancer diagnosed in 2002 to 2005 and 1,313 controls were interviewed in person about the use of HT and other characteristics. Women who used a single form of therapy (ET or EPT) were compared with women who never used HT using logistic regression to calculate odds ratios (OR) and 95% confidence intervals (95% CIs). Risk was increased among current or recent (within the last 3 years) users of ET with 5 years of use (ORs, 95% CIs: 1.6, 1.1-2.5 and 1.8, 0.8-3.7, respectively). Little increase in risk was noted among long-term ET users who discontinued use in the more distant past (OR, 1.2; 95% CI, 0.6-2.6). No increase in risk was noted among women who used only EPT, regardless of duration. Compared with women who never used HT, current users of EPT had an OR of 1.1 (95% CI, 0.8-1.5), and risk declined with increasing time since stopping; the OR was 0.7 (95% CI, 0.4-1.0) among women who had discontinued EPT within the last 3 years and 0.5 (95% CI, 0.3-0.7) among women who stopped at an earlier point. Long-term ET may be associated with an increased ovarian cancer risk that wanes after use ceases. We did not observe an increased risk with EPT, and with increasing time after stopping, a reduction in risk became increasingly evident. The progestogen component of HT may confer a risk reduction that is masked by an opposing effect of estrogen until, among former users, estrogenic influences have diminished. These findings, if replicated, may have implications both for public health and development of chemoprevention strategies. (Cancer Epidemiol Biomarkers Prev 2007;16(12):2548–56)

Commentary

Ovarian Cancer and Menopausal Hormone Therapy: More Data and New Questions

James V. Lacey, Jr.
Cancer Epidemiol. Biomarkers Prev. 2007 16: 2524-2525. [Full Text] [PDF]

This article has been cited by other articles:

				H. Song, S. J. Ramus, S. K. Kjaer, R. A. DiCioccio, G. Chenevix-Trench, C. L. Pearce, E. Hogdall, A. S. Whittemore, V. McGuire, C. Hogdall, et al. Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study Hum. Mol. Genet., June 15, 2009; 18(12): 2297 - 2304. [Abstract] [Full Text] [PDF]

				R. T. Palmieri, M. A. Wilson, E. S. Iversen, M. A. Clyde, B. Calingaert, P. G. Moorman, C. Poole, A. R. Anderson, S. Anderson, H. Anton-Culver, et al. Polymorphism in the IL18 Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3567 - 3572. [Abstract] [Full Text] [PDF]

				C. G. Hannibal, M. A. Rossing, K. G. Wicklund, and K. L. Cushing-Haugen Analgesic Drug Use and Risk of Epithelial Ovarian Cancer Am. J. Epidemiol., June 15, 2008; 167(12): 1430 - 1437. [Abstract] [Full Text] [PDF]

				Y. J. Song, A. R. Kristal, K. G. Wicklund, K. L. Cushing-Haugen, and M. A. Rossing Coffee, Tea, Colas, and Risk of Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 712 - 716. [Abstract] [Full Text] [PDF]

				J. V. Lacey Jr. Ovarian Cancer and Menopausal Hormone Therapy: More Data and New Questions Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2524 - 2525. [Full Text] [PDF]